Market Overview:
The global lipid metabolism disease drug market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of obesity and diabetes, rising geriatric population, and technological advancements in the field of lipid metabolism disease drugs. The global lipid metabolism disease drug market is segmented on the basis of type into OTC drugs and Rx drugs. The Rx drugs segment is further sub-segmented into statins, fibrates, niacin derivatives, bile acid sequestrants, and others. Statins are the most commonly prescribed class of cholesterol-lowering medications and are expected to dominate the global lipid metabolism disease drug market during the forecast period. On the basis of application, this market is segmented into hospital pharmacies and retail pharmacies. Geographically, it is analyzed across North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U K), Asia Pacific (Japan China India Australia South Korea) Middle East & Africa(GCC Countries Turkey Nigeria South Africa).
Product Definition:
Lipid Metabolism Disease Drug is a drug used to treat lipid metabolism diseases. These diseases are caused by problems with the way the body breaks down and uses fats and cholesterol. The drug helps improve the body's ability to use these substances, which can help lower blood cholesterol levels and reduce the risk of heart disease.
OTC:
OTC stands for Over The Counter and is a category of pharmaceutical products that do not require prescription. OTC drugs are sold directly to consumers without any involvement of a healthcare professional. Most OTC drugs fall under the category of nutraceuticals, which are foods or natural supplements that help in maintaining health by improving body function or supporting proper body function. Some examples include vitamins, minerals, herbal supplements and amino acids used for weight loss or muscle building among others.
Rx Drugs:
Rx drugs are the ones that are used to treat a disease or to help recover from an injury. The drug is given to the patient and then it goes through different metabolic pathways in order to get into the cells and do its work. In case of Lipid metabolism disease, there is a problem with lipid metabolism which causes accumulation of fat in many tissues including liver, heart, muscle etc.
Application Insights:
The global market is categorized into hospital, retail pharmacy and others.
Retail pharmacies are expected to witness lucrative growth over the forecast period due to increasing awareness about treatment options among patients as well as availability of drugs at affordable prices through this channel. Rising preference for self-medication and increasing incidences of lifestyle disorders are also likely to contribute toward revenue growth during the forecast period.
The growing geriatric population prone to developing lifestyle disorders is another factor anticipated to drive demand for these medications in near future.
Regional Analysis:
North America was the leading revenue contributor in 2017. The presence of a large number of players, advanced healthcare infrastructure, and high disease prevalence are some factors attributing to its large share. Moreover, the introduction of novel therapies for treatment and management of LDMD is expected to drive growth over the forecast period.
Asia Pacific is estimated to be one of the fastest-growing regions during the forecast period owing to rising disposable income levels and improving economic conditions in emerging countries such as India & China.
Growth Factors:
- Increasing prevalence of obesity and lipid metabolism diseases across the globe.
- Growing awareness about the benefits of lipid metabolism drugs among people.
- Rising demand for novel and effective lipid metabolism drugs by consumers.
- Technological advancements in drug development that would lead to better and safer lipid metabolism drugs in the marketplaces 5 Increased research and development activities by pharmaceutical companies for novel lipid metabolism therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Lipid Metabolism Disease Drug Market Research Report
By Type
OTC, Rx Drugs
By Application
Hospital, Retail Pharmacy
By Companies
Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
154
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Lipid Metabolism Disease Drug Market Report Segments:
The global Lipid Metabolism Disease Drug market is segmented on the basis of:
Types
OTC, Rx Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Novartis
- Takeda Pharmaceutical
- Astra Zeneca
- Boehringer Ingelheim
- KOWA
- Kythera
- Fuji yakuhin
- LG Life Science
- Metsubishi Tanabe Pharma
- Merck
Highlights of The Lipid Metabolism Disease Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- OTC
- Rx Drugs
- By Application:
- Hospital
- Retail Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lipid Metabolism Disease Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lipid metabolism disease drug is a medication used to treat lipid metabolism diseases. These diseases are caused by a problem with the way the body uses fats and cholesterol.
Some of the major players in the lipid metabolism disease drug market are Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin, LG Life Science, Metsubishi Tanabe Pharma, Merck.
The lipid metabolism disease drug market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lipid Metabolism Disease Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Lipid Metabolism Disease Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Lipid Metabolism Disease Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Lipid Metabolism Disease Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Lipid Metabolism Disease Drug Market Size & Forecast, 2020-2028 4.5.1 Lipid Metabolism Disease Drug Market Size and Y-o-Y Growth 4.5.2 Lipid Metabolism Disease Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 OTC
5.2.2 Rx Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lipid Metabolism Disease Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lipid Metabolism Disease Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 OTC
9.6.2 Rx Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 OTC
10.6.2 Rx Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 OTC
11.6.2 Rx Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 OTC
12.6.2 Rx Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 OTC
13.6.2 Rx Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lipid Metabolism Disease Drug Market: Competitive Dashboard
14.2 Global Lipid Metabolism Disease Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Novartis
14.3.3 Takeda Pharmaceutical
14.3.4 Astra Zeneca
14.3.5 Boehringer Ingelheim
14.3.6 KOWA
14.3.7 Kythera
14.3.8 Fuji yakuhin
14.3.9 LG Life Science
14.3.10 Metsubishi Tanabe Pharma
14.3.11 Merck